{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:02:06Z","timestamp":1789786926040,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005054","name":"Nantong University","doi-asserted-by":"publisher","award":["2024JY061"],"award-info":[{"award-number":["2024JY061"]}],"id":[{"id":"10.13039\/501100005054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012218","name":"Xuzhou Medical University Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy","doi-asserted-by":"publisher","award":["25KF15"],"award-info":[{"award-number":["25KF15"]}],"id":[{"id":"10.13039\/501100012218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018557","name":"Science and Technology Project of Nantong City","doi-asserted-by":"publisher","award":["MS2024053"],"award-info":[{"award-number":["MS2024053"]}],"id":[{"id":"10.13039\/501100018557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117717","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:54:18Z","timestamp":1787813658000},"page":"117717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Isolation, structural elucidation and cytotoxicity evaluation of novel degradation impurities of futibatinib"],"prefix":"10.1016","volume":"282","author":[{"given":"Liangliang","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117717_bib1","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jpba.2026.117717_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpba.2026.117717_bib3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.21037\/hbsn-23-411","article-title":"The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma-unveiling the future challenges in drug therapy","volume":"12","author":"Nishida","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.jpba.2026.117717_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11523-024-01059-8","article-title":"Futibatinib: a review in locally advanced and metastatic cholangiocarcinoma","volume":"19","author":"Hoy","year":"2024","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jpba.2026.117717_bib5","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-23-1042","article-title":"FDA approval summary: futibatinib for unresectable advanced or metastatic, chemotherapy refractory intrahepatic cholangiocarcinoma with FGFR2 fusions or other rearrangements","volume":"29","author":"Gandhy","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2026.117717_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"FOENIX-CCA2 study investigators, futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2026.117717_bib7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2026.117717_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jpba.2026.117717_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115262","article-title":"Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications","volume":"218","author":"Satoh","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jpba.2026.117717_bib10","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2026.117717_bib11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpba.2026.117717_bib12","series-title":"Q3A(R2): Impurities in New Drug Substances","author":"International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH)","year":"2006"},{"key":"10.1016\/j.jpba.2026.117717_bib13","series-title":"Q3B(R2): Impurities in New Drug Products","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2006"},{"key":"10.1016\/j.jpba.2026.117717_bib14","series-title":"Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"1999"},{"key":"10.1016\/j.jpba.2026.117717_bib15","series-title":"Q1A(R2): Stability Testing of New Drug Substances and Products","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2003"},{"key":"10.1016\/j.jpba.2026.117717_bib16","series-title":"Q1B: Photostability Testing of New Drug Substances and Products","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"1996"},{"key":"10.1016\/j.jpba.2026.117717_bib17","series-title":"M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2023"},{"key":"10.1016\/j.jpba.2026.117717_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114731","article-title":"Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS\/MS: application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance","volume":"214","author":"Tang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117717_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2024.124543","article-title":"Spectrofluorometric determination of futibatinib in human plasma and pharmaceutical formulations","volume":"320","author":"Alzhrani","year":"2024","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2026.117717_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115403","article-title":"Separation and structural characterization of unknown impurity in vancomycin by two-dimensional preparative liquid chromatography, LC-MS and NMR","volume":"232","author":"Wang","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117717_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.70027","article-title":"Application of advanced high-resolution mass spectrometric techniques for the analysis of losartan potassium drug substance degradation products: from nontargeted to targeted screening","volume":"47","author":"Xia","year":"2024","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2026.117717_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113196","article-title":"Characterization of two unknown impurities in roxithromycin by 2D LC-QTOF\/MS\/MS and NMR","volume":"184","author":"Wang","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117717_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116747","article-title":"Separation, characterization and cytotoxicity of unknown forced degradation impurity of selpercatinib using Prep-LC, HRMS and NMR","volume":"258","author":"Wang","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117717_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115280","article-title":"LC-HRMS and NMR studies for characterization of forced degradation impurities of ponatinib, a tyrosine kinase inhibitor: insights into in-silico degradation and toxicity profiles","volume":"227","author":"Golla","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117717_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs - a review","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2026.117717_bib26","doi-asserted-by":"crossref","first-page":"13075-80","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:32:19Z","timestamp":1789785139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526003857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":26,"alternative-id":["S0731708526003857"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117717","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation, structural elucidation and cytotoxicity evaluation of novel degradation impurities of futibatinib","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117717"}}